Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
Volatility and Risk
Caribou Biosciences has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Profitability
This table compares Caribou Biosciences and Larimar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Caribou Biosciences | -1,030.42% | -89.11% | -62.47% |
| Larimar Therapeutics | N/A | -137.39% | -97.65% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Caribou Biosciences | 1 | 0 | 3 | 1 | 2.80 |
| Larimar Therapeutics | 1 | 0 | 6 | 3 | 3.10 |
Caribou Biosciences currently has a consensus price target of $7.75, indicating a potential upside of 372.56%. Larimar Therapeutics has a consensus price target of $11.67, indicating a potential upside of 174.51%. Given Caribou Biosciences’ higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Larimar Therapeutics.
Institutional and Insider Ownership
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Caribou Biosciences and Larimar Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Caribou Biosciences | $11.16 million | 15.75 | -$148.12 million | ($1.08) | -1.52 |
| Larimar Therapeutics | N/A | N/A | -$165.67 million | ($1.95) | -2.18 |
Caribou Biosciences has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats Larimar Therapeutics on 9 of the 14 factors compared between the two stocks.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
